StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Biogen's price to sales ratio was 3.7× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 1.8× to 4.3×, with a median of 3.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.7×+1.2
2025Dec 31, 20252.6×+0.2
2024Dec 31, 20242.3×−1.4
2023Dec 29, 20233.8×−0.2
2022Dec 30, 20223.9×+0.6
2021Dec 31, 20213.3×+0.4
2020Dec 31, 20202.9×−1.2
2019Dec 31, 20194.0×−0.7
2018Dec 31, 20184.7×−1.0
2017Dec 29, 20175.8×+0.3
2016Dec 30, 20165.5×−1.4
2015Dec 31, 20156.8×−2.1
2014Dec 31, 20148.9×−1.5
2013Dec 31, 201310.4×+3.3
2012Dec 31, 20127.1×+1.2
2011Dec 30, 20115.9×+1.6
2010Dec 31, 20104.3×+0.7
2009Dec 31, 20093.6×–

More Biogen figures

See a number that looks wrong?